These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 16310897)

  • 1. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
    Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
    de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
    Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
    Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
    Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
    Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood mononuclear cell supernatants from asymptomatic dogs immunized and experimentally challenged with Leishmania chagasi can stimulate canine macrophages to reduce infection in vitro.
    Rodrigues CA; Batista LF; Teixeira MC; Pereira AM; Santos PO; de Sá Oliveira GG; de Freitas LA; Veras PS
    Vet Parasitol; 2007 Feb; 143(3-4):197-205. PubMed ID: 17045743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
    Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
    Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.
    Shahbazi M; Zahedifard F; Saljoughian N; Doroud D; Jamshidi S; Mahdavi N; Shirian S; Daneshbod Y; Hamid Zarkesh-Esfahani S; Papadopoulou B; Rafati S
    Vet Parasitol; 2015 Sep; 212(3-4):130-9. PubMed ID: 26255093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
    Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P; Saxena S; Madhubala R
    Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.